Results 1 to 10 of about 21,288 (167)

A Multiple-Model-Informed Drug-Development Approach for Optimal Regimen Selection of an Oncolytic Virus in Combination With Pembrolizumab. [PDF]

CPT Pharmacometrics Syst Pharmacol
ABSTRACT The antitumor efficacy of an intratumoral injection of a genetically engineered oncolytic vaccinia virus carrying human IL‐7 and murine IL‐12 genes (hIL‐7/mIL‐12‐VV) was demonstrated in CT26.WT‐bearing mice. In the CT26.WT‐bearing mouse model, the efficacy of the combination of hIL‐7/mIL‐12‐VV plus the anti‐programmed cell death protein (PD)‐1
Yamada A, Choules MP, Brightman FA, Takeshita S, Nakao S, Amino N, Nakayama T, Takeuchi M, Komatsu K, Ortega F, Mistry H, Orrell D, Chassagnole C, Bonate PL.   +13 more
europepmc   +2 more sources

Chinese expert consensus on clinical application of recombinant oncolytic adenovirus in the treatment of malignant tumors [PDF]

Zhongguo aizheng zazhi, 2023
Treatment using oncolytic virus as a new tumor immunologic agent has made continuous breakthroughs in basic and clinical research of tumor in recent years, and it is expected to play an important role in cancer immunotherapy in the future.
Expert Committee on Immunotherapy of Chinese Society of Clinical Oncology , Professional Committee on Cancer Biotherapy of Shanghai Anticancer Association
doaj   +1 more source

Oncolytic H-1 Parvovirus Hijacks Galectin-1 to Enter Cancer Cells

Viruses, 2022
Clinical studies in glioblastoma and pancreatic carcinoma patients strongly support the further development of H-1 protoparvovirus (H-1PV)-based anticancer therapies. The identification of cellular factors involved in the H-1PV life cycle may provide the
Tiago Ferreira, Amit Kulkarni, Clemens Bretscher, Petr V. Nazarov, Jubayer A. Hossain, Lars A. R. Ystaas, Hrvoje Miletic, Ralph Röth, Beate Niesler, Antonio Marchini   +9 more
doaj   +1 more source

Oncolytic H-1 parvovirus binds to sialic acid on laminins for cell attachment and entry

Nature Communications, 2021
Rat H-1 parvovirus (H-1PV) is in clinical development for oncolytic therapy. Here, Kulkarni et al. identify LAMC1 as a modulator of H-1PV cell attachment and entry and find that LAMC1 levels and H-1PV oncolytic activity correlate in 59 tested cancer cell
Amit Kulkarni, Tiago Ferreira, Clemens Bretscher, Annabel Grewenig, Nazim El-Andaloussi, Serena Bonifati, Tiina Marttila, Valérie Palissot, Jubayer A. Hossain, Francisco Azuaje, Hrvoje Miletic, Lars A. R. Ystaas, Anna Golebiewska, Simone P. Niclou, Ralf Roeth, Beate Niesler, Amélie Weiss, Laurent Brino, Antonio Marchini   +18 more
doaj   +1 more source

The XVIII International Parvovirus Workshop Rimini, Italy, 14–17 June 2022

Viruses, 2023
The XVIII International Parvovirus Workshop took place in Rimini, Italy, from 14 to 17 June 2022 as an on-site event, continuing the series of meetings started in 1985 and continuously held every two years.
Giorgio Gallinella, Antonio Marchini
doaj   +1 more source

Oncolytic H-1 Parvovirus Enters Cancer Cells through Clathrin-Mediated Endocytosis

Viruses, 2020
H-1 protoparvovirus (H-1PV) is a self-propagating virus that is non-pathogenic in humans and has oncolytic and oncosuppressive activities. H-1PV is the first member of the Parvoviridae family to undergo clinical testing as an anticancer agent.
Tiago Ferreira, Amit Kulkarni, Clemens Bretscher, Karsten Richter, Marcelo Ehrlich, Antonio Marchini   +5 more
doaj   +1 more source

Recent advances in oncolytic virus therapy for hepatocellular carcinoma

Frontiers in Oncology, 2023
Hepatocellular carcinoma (HCC) is a highly refractory cancer and the fourth leading cause of cancer-related mortality worldwide. Despite the development of a detailed treatment strategy for HCC, the survival rate remains unsatisfactory.
Licheng Zhu, Licheng Zhu, Yu Lei, Yu Lei, Jia Huang, Jia Huang, Yahang An, Yanqiao Ren, Yanqiao Ren, Lei Chen, Lei Chen, Huangxuan Zhao, Huangxuan Zhao, Chuansheng Zheng, Chuansheng Zheng   +14 more
doaj   +1 more source

Oncolytic Viruses: Immunotherapy Drugs for Gastrointestinal Malignant Tumors

Frontiers in Cellular and Infection Microbiology, 2022
Oncolytic virus therapy has advanced rapidly in recent years. Natural or transgenic viruses can target tumor cells and inhibit tumor growth and metastasis in various ways without interfering with normal cell and tissue function.
Qingbo Li, Patrick Kwabena Oduro, Rui Guo, Rui Guo, Ruiqiao Li, Ling Leng, Xianbin Kong, Qilong Wang, Long Yang, Long Yang   +9 more
doaj   +1 more source

Oncolytic Virotherapy for Cancer: Clinical Experience

Biomedicines, 2021
Oncolytic viruses are a new class of therapeutics which are largely in the experimental stage, with just one virus approved by the FDA thus far. While the concept of oncolytic virotherapy is not new, advancements in the fields of molecular biology and ...
Shyambabu Chaurasiya, Yuman Fong, Susanne G. Warner   +2 more
doaj   +1 more source

H-1 Parvovirus as a Cancer-Killing Agent: Past, Present, and Future

Viruses, 2019
The rat protoparvovirus H-1PV is nonpathogenic in humans, replicates preferentially in cancer cells, and has natural oncolytic and oncosuppressive activities. The virus is able to kill cancer cells by activating several cell death pathways.
Clemens Bretscher, Antonio Marchini
doaj   +1 more source